clinical trial · NCT04106414
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Endometrial AdenocarcinomaEndometrial CarcinosarcomaNivolumabBMS- 986205
brief summary
This study will compare the effects of treatment with nivolumab alone versus those of nivolumab plus the experimental drug BMS-986205. Adding BMS-986208 to nivolumab could shrink the cancer or prevent it from returning, but it could also cause side effects.
started
Sep 24, 2019
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Oct 16, 2026
official title
A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol